Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
CRVO similar filings
- 22 Jul 16 Submission of Matters to a Vote of Security Holders
- 16 May 16 Diffusion Pharmaceuticals Provides Corporate Highlights and Reports First Quarter 2016 Results
- 1 Apr 16 Departure of Directors or Certain Officers
- 25 Mar 16 Changes in Registrant's Certifying Accountant
- 27 Jan 16 Diffusion Pharmaceuticals AnnouncesStock Ticker Symbol Change to DFFN
- 14 Jan 16 Amendments to Articles of Incorporation or Bylaws
- 8 Jan 16 Diffusion Pharmaceuticals Completes Merger with RestorGenexand Becomes a Publicly TradedOncology-Focused BiotechnologyCompany
Filing view
External links
Exhibit 16.2
March 25, 2016
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Diffusion Pharmaceuticals Inc.’s Form 8-K/A dated March 25, 2016, and have the following comments:
1. | We agree with the statements made in paragraphs one through four. |
2. | We have no basis to agree or disagree with the statements made in paragraphs five and six. |
Yours truly,
/s/ Deloitte & Touche LLP